RVL Pharmaceuticals plc Ordinary Shares
RVLP
RVLP was delisted on the 20th of October, 2023.
36 hedge funds and large institutions have $28.2M invested in RVL Pharmaceuticals plc Ordinary Shares in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 10 closing their positions.
9,650% more call options, than puts
Call options by funds: $195K | Put options by funds: $2K
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
1.27% more ownership
Funds ownership: 24.25% → 25.52% (+1.3%)
22% less funds holding
Funds holding: 46 → 36 (-10)
44% less capital invested
Capital invested by funds: $50.5M → $28.2M (-$22.3M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
90% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.69M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$431K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$169K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$50.2K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$40.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$122K |
| 2 |
Renaissance Technologies
New York
|
-$90.5K |
| 3 |
IIA
IPG Investment Advisors
San Diego,
California
|
-$36.8K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$34K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$32K |
RVLP Hedge Fund Activity: Q4 2022 in Review
36 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q4 2022, worth a combined $28.2M — down 44% from $50.5M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of RVLP and 1 opened new positions — a net loss of 9 holders — while 6 trimmed existing stakes and 12 added.
The largest buyer was AIGH Capital Management, adding an estimated $1.69M. The largest seller was Morgan Stanley, cutting an estimated $122K.
- 36 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q4 2022, down from 46 in Q3 2022.
- Funds reported $28.2M of RVL Pharmaceuticals plc Ordinary Shares stock for Q4 2022, down 44% quarter-over-quarter.
- 1 fund opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q4 2022 and 10 closed out, a net change of -9 holders.
- The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q4 2022 was AIGH Capital Management, an estimated $1.69M added.
- The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q4 2022 was Morgan Stanley, an estimated $122K sold.
Based on aggregated 13F filings for Q4 2022.